Aprea Therapeutics, Inc. (APRE)
Nasdaq · Healthcare · Biotechnology
$0.6756−3.51%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $8.5M
- 52-week range
- $0.548 – $1.69
- 52-week change
- −53.20%
- EPS (trailing)
- −$0.95
Fiscal year to Dec 2025
- Net income
- −$12.6M
- Diluted EPS
- −$1.93
From the company’s annual report on SEC EDGAR.
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Headquarters: Doylestown, United States · 8 employees · aprea.com